Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02919917 · ClinicalTrials.gov registry record · Phase 2

Treatment of Post-SCI Hypotension

A Phase 2 study, sponsored by James J. Peters Veterans Affairs Medical Center.

Completed
Registry status
Phase 2
Development phase
66
Enrollment target

NCT02919917 is a Phase 2 study that has completed, run by James J. Peters Veterans Affairs Medical Center. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02919917, a Phase 2 study, has completed, sponsored by James J. Peters Veterans Affairs Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
66 participants
Enrollment target

Study Summary

While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters. Comprehensively documenting the impact of orthostatic hypotension (OH), regardless of symptoms, during acute rehabilitation and identifying the effects of two different treatment approaches on therapy participation and adherence to an intended rehabilitation plan could have a significant impact on clinical practice in the acute rehabilitation setting following SCI.

Interventions

  • DRUG Midodrine Hydrochloride

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2017-06-01
Est. Completion 2021-09-01
Phase Phase 2

What the Registry Record Tells You About NCT02919917

The ClinicalTrials.gov registry entry for NCT02919917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James J. Peters Veterans Affairs Medical Center, which has 39 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Midodrine Hydrochloride is the first listed.

NCT02919917 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02919917 about?

NCT02919917 is a clinical study titled "Treatment of Post-SCI Hypotension". While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters. Comprehensively documenting the impact of orthostatic hypotension (OH), regardless of symptoms, duri...

What is the current status of trial NCT02919917?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2017-06-01. Estimated completion is 2021-09-01.

What interventions are being tested in trial NCT02919917?

The interventions under investigation include: Midodrine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT02919917?

This trial is sponsored by James J. Peters Veterans Affairs Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.